A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- 30 November 2002
- journal article
- abstracts
- Published by Elsevier in European Journal Of Cancer
- Vol. 38, S153
- https://doi.org/10.1016/s0959-8049(02)81165-0
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: